Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 4/20 | 0.36 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.33 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.30 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18061768 | 1.00 | ACHE (0.36) | ACHECDK5CDK5R1KDM4EFGFR1 | |
| SCHEMBL26780401 | 1.00 | ACHE (0.36) | ACHECDK5CDK5R1KDM4EFGFR1 | |
| SCHEMBL13030113 | 0.93 | ACHE (0.43) | ACHE | |
| SCHEMBL31514886 | 0.93 | ACHE (0.43) | ACHE | |
| SCHEMBL7921755 | 0.85 | ACHE (0.37) | ACHECDK5CDK5R1KDM4EFGFR1 | |
| SCHEMBL19827872 | 0.83 | ACHE (0.41) | ACHE | |
| SCHEMBL15898744 | 0.83 | ACHE (0.34) | ACHE | |
| SCHEMBL18061767 | 0.83 | ACHE (0.41) | ACHE | |
| SCHEMBL10238972 | 0.83 | ACHE (0.34) | ACHE | |
| SCHEMBL15763414 | 0.81 | ACHE (0.34) | ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10946033-B2 | 2′-substituted-N6-substituted purine nucleotides for RNA virus treatment | Atea Pharmaceuticals, Inc. (US) | 2021-03-16 | — | — | US | disclosed |
| US-20210009628-A1 | Beta-D-2'-DEOXY-2'-Alpha-FLUORO-2'-Beta-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT | Atea Pharmaceuticals, Inc. (US) | 2021-01-14 | — | — | US | disclosed |
| US-20190201433-A1 | 2'-SUBSTITUTED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR RNA VIRUS TREATMENT | Atea Pharmaceuticals, Inc. (US) | 2019-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210009628-A1 | Beta-D-2'-DEOXY-2'-Alpha-FLUORO-2'-Beta-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT | NSUN2, NUDT1, DCTD | ACHE 4553/4885CDK5 3615/4885CDK5R1 3758/4885 |
| US-10946033-B2 | 2′-substituted-N6-substituted purine nucleotides for RNA virus treatment | NSUN2, ADAR, NSUN3 | ACHE 4821/4885CDK5 3101/4885CDK5R1 3017/4885 |
| US-20190201433-A1 | 2'-SUBSTITUTED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR RNA VIRUS TREATMENT | NSUN2, ADAR, NSUN3 | ACHE 4803/4885CDK5 3137/4885CDK5R1 2989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.